Sanofi ADR (SNY) concluded trading on Thursday at a closing price of $57.75, with 2.97 million shares of worth about $171.78 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -0.65% during that period and on March 13, 2025 the price saw a gain of about 0.10%. Currently the company’s common shares owned by public are about 2.61B shares, out of which, 2.51B shares are available for trading.
Stock saw a price change of -2.81% in past 5 days and over the past one month there was a price change of 7.14%. Year-to-date (YTD), SNY shares are showing a performance of 19.74% which increased to 19.44% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $45.22 but also hit the highest price of $60.12 during that period. The average intraday trading volume for Sanofi ADR shares is 2.62 million. The stock is currently trading 2.90% above its 20-day simple moving average (SMA20), while that difference is up 8.43% for SMA50 and it goes to 10.68% higher than SMA200.
Sanofi ADR (NASDAQ: SNY) currently have 2.61B outstanding shares and institutions hold larger chunk of about 10.56% of that.
The stock has a current market capitalization of $144.79B and its 3Y-monthly beta is at 0.52. PE ratio of stock for trailing 12 months is 24.12, while it has posted earnings per share of $2.39 in the same period. Its PEG reads 1.99 and has Quick Ratio of 0.73 while making debt-to-equity ratio of 0.23. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SNY, volatility over the week remained 1.58% while standing at 1.32% over the month.
Stock’s fiscal year EPS is expected to rise by 19.25% while it is estimated to increase by 10.41% in next year. EPS is likely to shrink at an annualized rate of 12.14% for next 5-years, compared to annual growth of 13.05% made by the stock over the past 5-years.
Coverage by Argus stated Sanofi ADR (SNY) stock as a Buy in their note to investors on July 26, 2024, suggesting a price target of $60 for the stock. Stock get a Neutral rating from JP Morgan on December 05, 2023.
